Trial · NCT06206408
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
NCT06206408, Phase 3, Completed, Astellas Pharma Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause. Trials, record NCT06206408. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06206408
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
- NCT number
- NCT06206408
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 410 participants, actual
- Lead sponsor
- Astellas Pharma Inc
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, Placebo
- First posted
- 2024-01-16
- Last updated
- 2025-12-23
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS) | Baseline and Week 8 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. |
| Secondary | Mean change from baseline in the frequency of mild to severe VMS | Baseline and up to Week 12 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. |
| Secondary | Mean change from baseline in the frequency of moderate to severe VMS | Baseline and up to Week 12 | Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. |
| Secondary | Mean percent reduction in the frequency of mild to severe VMS from baseline | Baseline and up to Week 12 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Mean percent reduction will be reported. |
| Secondary | Mean percent reduction in the frequency of moderate to severe VMS from baseline | Baseline and up to Week 12 | Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported. |
| Secondary | Percent reduction of >/= 50% in the frequency of mild to severe VMS from baseline | Baseline and up to Week 12 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported. |
| Secondary | Percent reduction of >/= 75% in the frequency of mild to severe VMS from baseline | Baseline and up to Week 12 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported. |
| Secondary | Percent reduction of 100% in the frequency of mild to severe VMS from baseline | Baseline and up to Week 12 | Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day. Percent reduction of 100% will be reported. |
| Secondary | Percent reduction of >/= 50% in the frequency of moderate to severe VMS from baseline | Baseline and up to Week 12 | Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 50% will be reported. |
| Secondary | Percent reduction of >/= 75% in the frequency of moderate to severe VMS from baseline | Baseline and up to Week 12 | Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of \>/= 75% will be reported. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06206408
GET https://conductscience.org/api/trials/v1/NCT06206408/registered